Bessemer Group’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $30K | Hold |
574
| – | – | ﹤0.01% | 1817 |
|
|
2025
Q4 | $28K | Buy |
574
+331
| +136% | +$16.1K | ﹤0.01% | 1792 |
|
|
2025
Q3 | $12K | Buy |
243
+92
| +61% | +$3.71K | ﹤0.01% | 1899 |
|
|
2025
Q2 | $5K | Sell |
151
-141
| -48% | -$4.52K | ﹤0.01% | 2044 |
|
|
2025
Q1 | $10K | Sell |
292
-111
| -28% | -$3.93K | ﹤0.01% | 1788 |
|
|
2024
Q4 | $14K | Buy |
403
+141
| +54% | +$4.96K | ﹤0.01% | 1637 |
|
|
2024
Q3 | $8K | Sell |
262
-60
| -19% | -$1.87K | ﹤0.01% | 1765 |
|
|
2024
Q2 | $8K | Buy |
322
+231
| +254% | +$6.7K | ﹤0.01% | 1594 |
|
|
2024
Q1 | $3K | Sell |
91
-129
| -59% | -$3.84K | ﹤0.01% | 1896 |
|
|
2023
Q4 | $7K | Buy |
220
+50
| +29% | +$1.33K | ﹤0.01% | 1686 |
|
|
2023
Q3 | $5K | Buy |
170
+17
| +11% | +$517 | ﹤0.01% | 1758 |
|
|
2023
Q2 | $4K | Buy |
153
+45
| +42% | +$1.57K | ﹤0.01% | 1894 |
|
|
2023
Q1 | $4K | Sell |
108
-26
| -19% | -$1K | ﹤0.01% | 1707 |
|
|
2022
Q4 | $5K | Hold |
134
| – | – | ﹤0.01% | 1595 |
|
|
2022
Q3 | $5K | Hold |
134
| – | – | ﹤0.01% | 1715 |
|
|
2022
Q2 | $4K | Hold |
134
| – | – | ﹤0.01% | 1628 |
|
|
2022
Q1 | $4K | Sell |
134
-25
| -16% | -$766 | ﹤0.01% | 1621 |
|
|
2021
Q4 | $5K | Buy |
+159
| New | +$4.82K | ﹤0.01% | 1595 |
|
|
2021
Q1 | – | Sell |
-289
| Closed | -$7K | – | 1633 |
|
|
2020
Q4 | $7K | Buy |
+289
| New | +$6.22K | ﹤0.01% | 1344 |
|
|
2019
Q4 | – | Sell |
-275
| Closed | -$8K | – | 1753 |
|
|
2019
Q3 | $8K | Buy |
+275
| New | +$8.15K | ﹤0.01% | 1506 |
|
|
2019
Q1 | – | Sell |
-5,500
| Closed | -$183K | – | 1958 |
|
|
2018
Q4 | $183K | Hold |
5,500
| – | – | ﹤0.01% | 1002 |
|
|
2018
Q3 | $277K | Sell |
5,500
-900
| -14% | -$44.4K | ﹤0.01% | 920 |
|
|
2018
Q2 | $383K | Buy |
+6,400
| New | +$332K | ﹤0.01% | 843 |
|
|
2016
Q2 | – | Sell |
-38,723
| Closed | -$591K | – | 1440 |
|
|
2016
Q1 | $591K | Sell |
38,723
-176,424
| -82% | -$2.3M | ﹤0.01% | 532 |
|
|
2015
Q4 | $2.89M | Buy |
215,147
+38,512
| +22% | +$596K | 0.02% | 359 |
|
|
2015
Q3 | $2.48M | Buy |
176,635
+161,515
| +1,068% | +$3M | 0.01% | 370 |
|
|
2015
Q2 | $257K | Buy |
+15,120
| New | +$215K | ﹤0.01% | 722 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Bessemer Group's SUPN Position: Q1 2026 in Review
Bessemer Group held its Supernus Pharmaceuticals (SUPN) position steady in Q1 2026 at 574 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #1817.
Bessemer Group first reported a position in SUPN in Q2 2015 and has held it in 27 quarters since. The position peaked at $2.89M in Q4 2015. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Bessemer Group held 574 shares of Supernus Pharmaceuticals worth $30K as of Q1 2026.
- Bessemer Group left its Supernus Pharmaceuticals share count unchanged in Q1 2026.
- Supernus Pharmaceuticals made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #1817 holding.
- Bessemer Group first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 27 quarters since.
- Bessemer Group's Supernus Pharmaceuticals position peaked at $2.89M in Q4 2015.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.